LogicBio Therapeutics (OTCMKTS:LOGC) Reaches New 52-Week High – Here’s What Happened

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) reached a new 52-week high on Tuesday. The company traded as high as $15.45 and last traded at $15.3948, with a volume of 24,675 shares. The stock had previously closed at $15.29.

LogicBio Therapeutics Stock Performance

The stock has a market capitalization of $705.61 million, a PE ratio of -21.14 and a beta of 2.04. The firm’s fifty day moving average is $14.03 and its 200-day moving average is $9.96. The company has a current ratio of 1.87, a quick ratio of 1.24 and a debt-to-equity ratio of 0.29.

LogicBio Therapeutics (OTCMKTS:LOGC) last announced its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The business had revenue of $33.60 million for the quarter, compared to the consensus estimate of $33.60 million.

About LogicBio Therapeutics

LogicBio Therapeutics, Inc was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone.

LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications.